Vivos Therapeutics Q4 2023 GAAP EPS $(3.05) Misses $(1.91) Estimate, Sales $3.248M Miss $3.406M Estimate

Vivos Therapeutics, Inc. -6.30%

Vivos Therapeutics, Inc.

VVOS

2.23

-6.30%

Vivos Therapeutics (NASDAQ: VVOS) reported quarterly losses of $(3.05) per share which missed the analyst consensus estimate of $(1.91) by 59.69 percent. The company reported quarterly sales of $3.248 million which missed the analyst consensus estimate of $3.406 million by 4.64 percent. This is a 17.77 percent decrease over sales of $3.950 million the same period last year.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via